1 |
Clark EDB. 1998. Refolding of recombinant proteins. Curr. Opin. Biotechnol. 9: 157-163.
DOI
|
2 |
Cousens LS, Shuster JR, Gallegos C, Ku L, Stempien MM, Urdea MS, et al. 1987. High level expression of proinsulin in the yeast Saccharomyces cerevisiae. Gene 61: 265-275.
DOI
|
3 |
Cowley DJ, Mackin RB. 1997. Expression, purification and characterization of recombinant human proinsulin. FEBS Lett. 402: 124-130.
DOI
|
4 |
Kyte J, Doolittle RF. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157: 105-132.
DOI
|
5 |
Fischer BH, Sumner I, Goodenough P. 1993. Isolation, renaturation, and formation of disulfide bonds of eukaryotic proteins expressed in Escherichia coli as inclusion bodies. Biotechnol. Bioeng. 41: 3-13.
DOI
|
6 |
Gu Z, Weidenhaupt M, Ivanova N, Pavlov M, Xu B, Su ZG, Janson JC. 2002. Chromatographic methods for the isolation of, and refolding of proteins from Escherichia coli inclusion bodies. Protein Exp. Purif. 25: 174-179.
DOI
|
7 |
Kim CK, Lee SM, Jeong SM. 2010. High cell density cultivation of recombinant Escherichia coli for production of rat procarboxypeptidase B. Food Sci. Biotechnol. 19: 1627-1633.
DOI
|
8 |
Lee SY, Oh SJ, Kim CK, Son YJ, Park KH, Min CK, et al. 2006. Plasmids expressing human insulin and the preparation method for human insulin thereby. United States Patent Application Publication US 2006, 0035316 A1.
|
9 |
Lilie H, Schwarz E, Rudolph R. 1998. Advances in refolding of proteins produced in E. coli. Curr. Opin. Biotechnol. 9: 497-501.
DOI
|
10 |
Linde S, Welinder BS, Nielsen JH. 1993. Analysis of proinsulin and its conversion products by reversed-phase high-performance liquid-chromatography. J. Chromatogr. B 614: 185-204.
DOI
|
11 |
Markussen J. 1985. Comparative reduction/oxidation studies with single chain des-(B30) insulin and porcine proinsulin. Int. J. Pept. Protein Res. 25: 431-434.
DOI
|
12 |
Qiao ZS, Guo ZY, Feng YM. 2001. Putative disulfide-forming pathway of porcine insulin precursor during its refolding in vitro. Biochemistry 40: 2662-2668.
DOI
|
13 |
Murray HD, Appleman JA, Gourse RL. 2003. Regulation of the Escherichia coli rrnB P2 promoter. J. Bacteriol. 185: 28-34.
DOI
|
14 |
Naglak TJ, Wang HY. 1990. Recovery of a foreign protein from the periplasm of Escherichia coli by chemical permeabilization. Enzyme Microb. Technol. 12: 603-611.
DOI
|
15 |
Nilsson J, Jonasson P, Samuelsson E, Stahl S, Uhlen M. 1996. Integrated production of human insulin and its C-peptide. J. Biotechnol. 48: 241-250.
DOI
|
16 |
Rudolph R, Lilie H. 1996. In vitro folding of inclusion body proteins. FASEB J. 10: 49-56.
DOI
|
17 |
Schnaitman CA. 1971. Effect of ethylene diamine tetraacetic acid, Triton X-100, and lysozyme on the morphology and chemical composition of isolated cell walls of Escherichia coli. J. Bacteriol. 108: 553-563.
|
18 |
Middelberg APJ, O’Neill BK. 1991. Monitoring the centrifugal recovery of recombinant protein inclusion bodies. Aust. J. Biotechnol. 5: 87-92.
|
19 |
Middelberg APJ. 2002. Preparative protein refolding. Trends Biotechnol. 20: 437-443.
DOI
|
20 |
Schutte H, Kula MR. 1990. Pilot- and process-scale techniques for cell disruption. Biotechnol. Appl. Biochem. 12: 599-620.
|
21 |
Son YJ, Kim CK, Choi BT, Park YC, Seo JH. 2008. Effects of β-mercaptoethanol and hydrogen peroxide on enzymatic conversion of human proinsulin to insulin. J. Microbiol. Biotechnol. 18: 983-989.
|
22 |
Enfors SO. 1992. Control of in vivo proteolysis in the production of recombinant proteins. TIBTECH 10: 310-315.
DOI
|
23 |
Son YJ, Park KH, Lee SY, Oh SJ, Kim CK, Choi BT, et al. 2007. Effect of temperature shift strategies on human preproinsulin production in the fed-batch fermentation of recombinant E. coli. Biotechnol. Bioprocess Eng. 12: 556-561.
DOI
|
24 |
Tikhonov RV, Pechenov SE, Belacheu IA, Yakimov SA, Klyushnichenko VE, Boldireva EF, et al. 2001. Recombinant human insulin VIII. Isolation of fusion protein-S-sulfonate, biotechnological precursor of human insulin, from the biomass of transformed Escherichia coli cells. Protein Exp. Purif. 21: 176-182.
DOI
|
25 |
Tsumoto K, Ejima D, Kumagai I, Arakawa T. 2003. Practical considerations in refolding proteins from inclusion bodies. Protein Exp. Purif. 28: 1-8.
DOI
|
26 |
Walsh G. 2005. Therapeutic insulins and their large-scale manufacture. Appl. Microbiol. Biotechnol. 67: 151-159.
DOI
|
27 |
Wang XM, Guo ZY. 2013. Recombinant expression, different downstream processing of the disulfide-rich anti-tumor peptide Ranpirnase and its effect on the growth of human glioma cell line SHG-44. Biomed. Rep. 5: 747-750.
|
28 |
Yon JM, Betton JM. 1991. Protein folding in vitro and in the cellular environment. Biol. Cell 71: 17-23.
DOI
|
29 |
Mukhopadhyay A. 1997. Inclusion bodies and purification of proteins in biologically active forms. Adv. Biochem. Eng. Biotechnol. 56: 61-109.
|
30 |
Son YJ, Kim CK, Kim YB, Kweon DH, Park YC, Seo JH. 2009. Effects of citraconylation on enzymatic modification of human proinsulin using trypsin and carboxypeptidase B. Biotechnol. Prog. 25: 1064-1070.
DOI
|
31 |
Clark EDB. 2001. Protein refolding for industrial processes. Curr. Opin. Biotechnol. 12: 202-207.
DOI
|
32 |
Bailey SM, Meagher MM. 2000. Separation of soluble protein from inclusion bodies in Escherichia coli lysate using crossflow microfiltration. J. Membr. Sci. 166: 137-146.
DOI
|
33 |
Bowden GA, Paredles AM, Georgiou G. 1991. Expression vectors based on the rac fusion promoter. Gene 42: 97-100.
|
34 |
Castellanos Serra LR, Hardy E, Ubieta R, Vispo NS, Fernandez C, Besada V, et al. 1996. Expression and folding of an interleukin-2-proinsulin fusion protein and its conversion into insulin by a single step enzymatic removal of the Cpeptide and the N-terminal fused sequence. FEBS Lett. 378: 171-176.
DOI
|